Endonovo Finalizing Plans to Develop a Telehealth Division

Endonovo Therapeutics Inc. is working with a prominent developer of telehealth (telemedicine) platforms to establish a new telehealth division for Endonovo.
 
“Endonovo’s Telehealth Division is expected to provide additional revenue and provide cost savings to the company and its customers of the platform. As Endonovo establishes itself in the medtech healthcare industry, it will seek out other medical device and pharmaceutical companies to generate additional revenue streams. Upon reaching revenue milestones, we believe we can spin-off the Telehealth Division as a medtech company to a major stock exchange,” CEO Alan Collier said.
 
“The collaboration aims to modernize the healthcare industry by leveraging advanced medical technology and digital solutions to provide accessible and efficient healthcare services to a wider population,” added Ira Weisberg, president of Endonovo’s Medical Division. “With Endonovo’s expertise as a developer of healthcare technology and our future telehealth developer’s extensive experience in telemedicine, this strategic partnership is poised to create a platform that seamlessly integrates telehealth services into the mainstream healthcare system.”
 
Forging Strategic Partnerships for Success
“By Endonovo developing and utilizing a complete telehealth platform, we are positioning Endonovo to become a leader in the evolving telehealth healthcare landscape. Incorporating a telehealth division into the current company structure will be instrumental in shaping Endonovo’s telehealth strategy, ensuring the delivery of cutting-edge solutions that meet the evolving needs of patients and healthcare providers,” Weisberg stated. his will allow us to leverage innovative solutions to expand our market reach and provide accessible, high-quality care to a wider patient population. Endonovo’s announcement to incorporate telehealth services into our company offerings represents a pivotal step forward towards driving growth, achieving cost savings, and enhancing patient satisfaction in the medical market. We are confident that our telehealth platform will generate significant revenue opportunities but also solidify our commitment to delivering exceptional pain and inflammation healthcare solutions and experiences for patient accessing our platform.”
 
Telehealth services are a rapidly growing technology within the medtech industry, thanks to the COVID-19 pandemic. According to a recent report by Reportlinker.com, the global market for telehealth is projected to reach $723.3 billion by 2030, growing 23% annually. The software and services segment is expected to expand 21.1% annually, reaching $462.8 billion by the end of the analysis period. The pandemic and recent expansion of medical services has served as a catalyst for telehealth growth as patients seek alternative ways to access healthcare services amid restrictions on in-person visits.
 
Telehealth Expansion Opportunities for SofPulse PEMF
The rise of telehealth and digital health technologies has opened new opportunities for healthcare providers to improve patient healthcare access and reduce costs by reaching patients in remote or underserved areas. In the rapidly evolving landscape of healthcare, the integration of telehealth solutions presents opportunities to enhance access to medical services and improve patient outcomes.
 
Endonovo’s SofPulse Pulsed Electro Magnetic Field (PEMF) Therapy—which can be used to treat pain and inflammation as a cost-effective and patient-friendly therapy—can expand exponentially through telehealth direct to consumer sales. By leveraging the power of telecommunication and digital platforms, telehealth eliminates geographical barriers, bringing medical expertise directly to patients through virtual consultations, remote monitoring and personalized care plans.
 
Patients will have the opportunity to call into the telehealth system and speak to an doctor regarding a health condition that could be treated or have benefits in utilizing SofPulse PEMF system. This approach enhances convenience and affordability. It also provides tremendous potential to improve overall healthcare delivery, empower patients and drive positive outcomes ensuring that their healthcare needs are met effectively.
 
Endonovo Therapeutics is currently structured into two divisions: Legacy, a commercial-stage developer primarily of noninvasive wearable Electroceuticals therapeutic devices for pain relief, general wellness and wound curatives with many of its products marketed under the SofPulse brand name; and Build Up Strategy, acquiring complementary specialty service providers of profitable biotechnology and specialty construction companies.